Anumana Expands AI Platform to Enhance Cardiovascular Care
Anumana, a leading AI-driven health technology company, has broadened its AI platform from diagnostic ECG-AI technology to perioperative and acute cardiac care. This expansion is fueled by a new investment from Boston Scientific Corporation as part of Anumana’s Series C financing round. The investment will accelerate the development of a multimodal generative AI platform and Software as a Medical Device (SaMD), while further establishing Anumana’s leadership in AI-powered cardiovascular diagnostics.
The Series C funding will support Anumana’s growth into perioperative cardiac care and the continued advancement of its ECG-AI algorithms toward regulatory milestones and commercial adoption in outpatient settings. It also underscores Anumana’s commitment to generating real-world evidence on the impact of ECG-AI in preventive cardiology. As part of this expansion, Anumana is developing novel generative AI imaging technologies to enhance complex cardiac interventions. These technologies will include real-time imaging platforms and predictive algorithms for various cardiac procedures.
Anumana will collaborate with Boston Scientific to create AI solutions for electrophysiology procedures, particularly for treating atrial fibrillation. These solutions will integrate seamlessly into clinical workflows, providing a new approach to intraoperative decision support. “This new investment validates Anumana’s strategic direction,” said Maulik Nanavaty, CEO of Anumana. “We’re extending our expertise in diagnostic cardiology AI into the perioperative setting, creating intuitive tools to interpret complex data in real time.”
Anumana’s multimodal AI systems leverage deep longitudinal data from millions of patients, enabling innovative AI solutions that support earlier diagnosis and improve treatment decisions. The company aims to advance AI cardiac tools that integrate into routine practice, enhancing patient outcomes.
The Series C financing round included participation from existing investors such as Matrix Capital, Mayo Clinic, and NTTVC. Anumana’s FDA-cleared ECG-AI LEF algorithm is available in the U.S. and eligible for reimbursement as of January 2025.
